| Health / Medical Topics |
MET/VEGFR-2 inhibitor GSK1363089
Pronunciation
A substance being studied in the treatment of cancer. MET/VEGFR-2 inhibitor GSK1363089 blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called foretinib and XL880. (NCI Dictionary)
YOU MAY ALSO LIKE
Human MET wild-type allele is located within 7q31 and is approximately 126 kb in length. This allele, which encodes hepatocyte growth factor…
An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein,…
An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Upon intravenous administration, c-Met…
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met,…
A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma…
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor EMD 1214063 selectively binds to MET tyrosine kinase…
